SARMs that binds to androgen receptors with high affinity (Ki ~ 1 nm) and selectivity. The drug is included in the class of ligands of androgen receptors, selectively affecting the tissues of the body. This class of drugs is developed to treat muscle wasting associated with cancer, acute and chronic diseases and age-related muscle atrophy. It is expected that the therapeutic effect of SARM is close to the action of testosterone, while the drug has improved safety, tolerability and responsiveness in patients, thanks to the tissue-selective mechanism of action and the oral route of administration. It should be noted that SARMS has a half-life of 24-36 hours and therefore it is easy enough to identify it on doping tests.
SARMS demonstrates anabolic activity in muscles, anti-restorative and anabolic activity in the bones and selectivity towards muscles and bones (without affecting the prostate and sebaceous glands). Recently, the first stage of the SARMS test was completed. In this randomized, double-blind, placebo-controlled study, the drug was given to healthy volunteers in the form of several increasing doses, in order to study the safety and tolerability of the drug in doses up to 22 mg.
Several recent studies have been devoted to finding the best and safest way to use the SARMS. The test results show that the drug act similar Boss Peptides an increase in muscle mass and a reduction in body fat, as well as a significant increase in strength, improvement in well-being and healing properties.
Increased muscle mass
SARMs causes the greatest increase in muscle mass. The results, however, will largely depend on the diet used. Users who achieve weight gain of up to 10 pounds or more significantly increase daily calorie intake when taking the drug. The recommended dosage for increasing muscle mass is 5-10 mg per day for 8 weeks.
Read also: Ibutamoren: Before and After Results
SARMs is excellently suited for use in body recomposition (simultaneous increase in muscle mass and decrease in fat mass while maintaining total body weight). For many users, the drug causes an increase in muscle mass and a reduction in body fat. The combination with other SARMs increases the likelihood of more noticeable body recombination. The recommended dose for this purpose will be 5-10 mg of the drug per day for 8 weeks.
Studies have shown that SARMs has minimal side effects. Suppression of the production of own testosterone is a dose-dependent phenomenon, but there is a decrease in the values of total and free testosterone, as well as SHBG (globulin, binding sex hormones). It is noteworthy that when SARMs was taken, there was no significant decrease in levels of LH (luteinizing hormone) or FSH (follicle-stimulating hormone). Thus, despite the overwhelming influence of SARMs on the production of testosterone, after its application, the recovery of the testosterone level occurs more quickly than after the application of anabolic. It was shown that the drug is not toxic and has mild, almost minimal, side effects. SARMs does not cause an increase in the level of estradiol, after the cycle of SARMs, it is recommended to undergo a complete course of restorative therapy. After the course of other SARMs, recovery therapy is usually not required, since the production of endogenous testosterone is almost not suppressed. Although SARMS does not suppress testosterone as much as anabolic, it acts much more powerful than other SARMs, so after the course of SARMS, a course of restorative therapy can be used to accelerate the recovery of endogenous testosterone production.